Cytokinetics, Inc. — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016; comparative period is Q1 2015. Cytokinetics is a clinical-stage biopharmaceutical company developing muscle-function therapies. It had no commercial drug sales; revenue primarily came from collaborations and grants. Unless noted, amounts below are in millions of dollars.
Financial performance and liquidity
| Metric | Q1 2016 | Q1 2015 | Change |
|---|---|---|---|
| Total revenue | $8.421 | $4.414 | +$4.007 |
| Research and development expense | $13.534 | $8.956 | +$4.578 |
| General and administrative expense | $6.841 | $4.367 | +$2.474 |
| Operating loss | $(11.954) | $(8.909) | Loss widened |
| Net loss | $(12.455) | $(8.872) | Loss widened |
| Basic and diluted loss per share | $(0.31) | $(0.23) | |
| Net cash from (used in) operating activities | $(17.507) | $34.359 |
Revenue increased about 91%, principally due to higher Astellas collaboration revenue. Operating expenses rose about 53%; higher outsourced clinical costs, mainly for the VITALITY-ALS trial, and increased personnel costs were key drivers. No gross margin was reported.
At March 31, cash and cash equivalents were $42.269; short- and long-term investments totaled $66.293, for combined cash, cash equivalents and investments of approximately $108.6, versus $111.6 at December 31, 2015. Management said existing resources were expected to fund requirements for at least 12 months. The company reported an accumulated deficit of $547.2 and expected continued operating losses and cash outflows.
Long-term debt had a $30.0 gross principal balance and a $29.466 carrying value, compared with a $14.639 carrying value at year-end 2015. The February 2016 additional $15.0 borrowing was under a loan agreement bearing 7.5% interest for the first two draws; debt interest expense was $0.6 in Q1. Repayment is in 36 equal installments beginning October 2017, with maturity in October 2020. The loans are secured by substantially all assets other than intellectual property; a further $10.0 draw is conditional. Total contractual debt and lease obligations were $46.272.
Material changes and business developments
- Collaboration revenue from Astellas was $7.653, versus $3.726 in Q1 2015, reflecting greater research reimbursements and license revenue recognition. Astellas deferred revenue was $16.3 at quarter-end. Amgen revenue was $0.617, versus $0.688.
- R&D spending increased particularly in the skeletal-muscle program, including tirasemtiv and CK-2127107. G&A growth reflected headcount and stock compensation, medical affairs and commercial-development work, and legal fees.
- Operating cash use was $17.5. Financing provided $14.9, mainly from the debt draw; investment purchases and maturities resulted in $20.2 of net investing cash use. The prior-year operating cash inflow included a significant related-party receivable collection.
- Common shares outstanding were 39.607 million at March 31. The company also had substantial potential dilution from warrants and options; Q1 diluted EPS excluded antidilutive instruments.
Outlook, programs and risks
- Company outlook: Management expected R&D and G&A expenses to increase significantly in 2016 compared with 2015. No specific numerical full-year revenue or expense guidance is stated in the provided filing text. The company had no product-sale revenue and said profitability was uncertain.
- Tirasemtiv / ALS: VITALITY-ALS enrollment target was increased from approximately 445 to 600; about 300 patients were enrolled at quarter-end. The company expected enrollment completion in the first half of 2016. The trial’s primary endpoint is change in slow vital capacity (SVC); regulators had not confirmed that SVC alone would support registration. The Q1 Data Monitoring Committee recommended continuing without changes. Tirasemtiv remains unpartnered, and further development requires substantial funding.
- CK-2127107: The Phase 2 SMA trial was ongoing, with enrollment completion expected in the second half of 2016. Astellas was expected to initiate a Phase 2 COPD trial in the first half of 2016. Astellas funds collaboration development, subject to Cytokinetics’ options and agreement terms.
- Omecamtiv mecarbil: Cytokinetics and Amgen held regulatory discussions and conducted planning for a potential Phase 3 program; a decision was expected in the coming months. Q1 2016 COSMIC-HF results previously reported improvements in prespecified secondary cardiac-function measures, with adverse events generally comparable to placebo. Amgen controls development and commercialization decisions.
- Funding and execution risks: The company may need additional equity, debt, grants or collaboration funding; such funding may be unavailable or dilutive or restrictive. Clinical efficacy, safety, enrollment, manufacturing, regulatory acceptance, partner decisions, and trial-vendor performance remain significant uncertainties. The filing notes prior failure of the tirasemtiv BENEFIT-ALS trial to meet its primary efficacy endpoint.
- Other matters: Cytokinetics’ lawsuit against clinical-trial data vendor Pharm-Olam seeking monetary damages remained pending; no gain was recorded. Management said it was not aware of indemnification matters expected to materially affect financial position, results or cash flows. Disclosure controls were assessed as effective, with no material change in internal control over financial reporting reported.
Key facts for investors to verify
- Whether VITALITY-ALS completed enrollment as planned, and the eventual efficacy and safety results and regulatory view of SVC as an endpoint.
- Current cash runway and burn rate, including the effect of rising trial and overhead costs and whether additional capital is required.
- Terms and conditions for access to the remaining $10.0 million under the loan agreement, covenant compliance, repayment obligations and secured assets.
- Progress and partner decisions for CK-2127107 and omecamtiv mecarbil, including clinical milestones and any resulting collaboration payments.
- How much reported revenue depends on Astellas and Amgen reimbursements and recognition of deferred collaboration consideration, rather than recurring product sales.
- Potential dilution from outstanding warrants, options, equity issuance capacity and any use of the at-the-market offering or shelf registration.